Bayer-Villiger monooxygenase variants with improved enzymatic activity and uses thereof
A Bayer-Billiger monooxygenase variant with enhanced activity addresses the limitations of existing enzymes by efficiently degrading polyketones and non-hydrolyzable plastics through amino acid substitution, enabling effective industrial utilization.
Patent Information
- Application Number
- KR1020220185423
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-12-27
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-12-27
AI Technical Summary
Existing redox enzymes, such as Baeyer-Villiger monooxygenases, are limited in industrial utility due to their dependence on coenzymes like NADP or NADPH, and there is a lack of efficient methods to screen and improve them, while enzymes for degrading non-hydrolyzable plastics like polyketones have not been precisely identified.
Development of a Bayer-Billiger monooxygenase variant with enhanced activity through amino acid substitution, particularly at the W93 position, and its use in combination with lipase for polyketone degradation.
The variant exhibits high activity in Bayer-Billiger oxidation reactions and effectively degrades polyketones, offering industrial applications in recycling and biological degradation of non-hydrolyzable plastics.
Smart Images

Figure 112022140356928-PAT00005_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a novel Bayer-Billiger monooxygenase variant and its uses, and more specifically, to a Bayer-Billiger monooxygenase variant characterized by an amino acid located at the active site of the Bayer-Billiger monooxygenase being modified to enhance the Bayer-Billiger monooxygenase reaction with respect to a substrate, a method for preparing the same, a method for Bayer-Billiger oxidation of a carbonyl group-containing compound using the variant, and the use of the variant in polyketone degradation. Background Technology
[0002] Generally, glucose oxidase, which is related to diabetes diagnosis (blood glucose sensors), has formed the largest market among redox enzymes. However, due to various drawbacks, research is being conducted on PQQ-GDH (pyrroloquinoline quinone-Glucose Dehydrogenase) as the second generation and FAD-GDH (Flavin Adenine Dinuclotide-Glucose Dehydrogenase) as the third generation market, but these also have problems such as poor enzyme stability. In addition, P450, dehydrogenase, reductase, Baeyer-Villiger monooxygenase, laccase, and peroxidase, which have various functions, are industrially very important in biosynthesis; however, the reason for the low development and utilization of redox biomaterials is that they are dependent on coenzymes such as NADP or NADPH and are very difficult to express.
[0003] Despite their high utility in various chemical reactions, the types of oxidative bio-components are very limited, and methods to efficiently screen and improve them are not only labor-intensive but also expensive and time-consuming. Among these redox enzymes with high industrial utility, Baeyer-Villiger monooxygenases (BVMOs) are NADP(H)-dependent flavonoids that are bio-components possessing Baeyer-Villiger oxidation activity, which involves adding oxygen between the carbons of carbonyl compounds, such as linear or cyclic ketones, to produce esters or lactones. The Baeyer-Villiger oxidation reaction is considered to be very unique among chemical reactions and can be used for the chemoenzymatic synthesis of useful compounds that are difficult to access chemically.
[0004] The use of enzymes in the Bayer-Billiger oxidation reaction not only simplifies industrial processes but also offers industrial advantages, such as avoiding the use of massive amounts of oxidizers that could pose a risk of explosion during transport and storage.
[0006] With the rapid increase in plastic waste, interest in the biological degradation of plastics is growing as a means of disposal. Plastics can be classified into hydrolyzable plastics, such as PET with ester bonds and PU with urethane bonds, and non-hydrolyzable plastics composed of carbon-carbon backbones. While the biological degradation of hydrolyzable plastics is relatively easy, non-hydrolyzable plastics are known to be difficult to decompose due to their strong hydrophobicity and large molecular weight, which hinders enzymatic access. Although microorganisms existing in nature that degrade non-hydrolyzable plastics have been reported, the specific enzymes involved in their degradation have not yet been precisely identified.
[0007] Since polyketones are oxidized forms of non-hydrolyzable plastics such as polyethylene and polypropylene and can be viewed as degradation products of these, enzymes capable of degrading polyketones could be industrially utilized for the biological degradation of non-hydrolyzable plastics.
[0009] Against this technical background, the inventors made diligent efforts to develop a Bayer-Billiger monooxygenase having excellent catalytic activity for the Bayer-Billiger oxidation reaction. As a result, they developed a Bayer-Billiger monooxygenase variant exhibiting high activity toward linear ketone substrates through amino acid substitution. Furthermore, they confirmed that polyketones can be degraded when the Bayer-Billiger monooxygenase variant is used in combination with lipase, thereby completing the present invention.
[0011] The information described above in the background section is intended solely to enhance understanding of the background of the present invention and may not include information that forms prior art already known to those skilled in the art to which the present invention belongs. The problem to be solved
[0013] The object of the present invention is to provide a Bayer-Billiger monooxygenase variant.
[0014] Another objective of the present invention is to provide a gene encoding the Bayer-Billiger monooxygenase variant, a recombinant vector comprising the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the Bayer-Billiger monooxygenase variant using the recombinant microorganism.
[0015] Another objective of the present invention is to provide a method for Bayer-Billiger oxidizing a compound containing a carbonyl group using the variant or the recombinant microorganism.
[0016] Another objective of the present invention is to provide a composition for polyketone degradation comprising the above-mentioned Bayer-Billiger monooxygenase variant and lipase. means of solving the problem
[0018] To achieve the above objective, the present invention provides a variant of Bayer-Billiger monooxygenase represented by SEQ ID NO. 1, comprising a mutation in the W93 amino acid.
[0019] The present invention also provides a gene encoding the biliger monooxygenase variant and a recombinant vector comprising the gene.
[0020] The present invention also provides a recombinant microorganism transformed with the gene or recombinant vector.
[0021] The present invention also comprises the step of culturing the recombinant microorganism to produce a Bayer-Billiger monooxygenase variant; and
[0022] The present invention provides a method for producing a Bayer-Billiger monooxygenase variant comprising the step of obtaining the Bayer-Billiger monooxygenase variant produced above.
[0023] The present invention also provides a method for Bayer-Billiger oxidizing a compound containing a carbonyl group using the variant or the recombinant microorganism.
[0024] The present invention also provides a composition for polyketone degradation comprising the above-mentioned Bayer-Billiger monooxygenase variant and lipase. Effects of the invention
[0026] The Bayer-Billiger monooxygenase variant according to the present invention exhibits high activity toward substrates having carbonyl groups, enabling it to perform the Bayer-Billiger oxidation reaction more efficiently than the wild-type enzyme. Furthermore, the Bayer-Billiger monooxygenase variant of the present invention can degrade polyketones when used in combination with lipase, thus allowing it to be utilized in the recycling industry. Brief explanation of the drawing
[0028] Figure 1 shows a method for constructing a vector containing a Bayer-Billiger monooxygenase gene with a site-saturated mutation. Figure 2 is a graph showing the results of random screening of PlBVMO variants using crude extracts of transformants into which a vector containing the mutated PlBVMO gene was inserted. Sequence analysis of the selected PlBVMO variants confirmed that W93-11 was variant W93Q, in which the 93rd amino acid tryptophan was substituted with glutamine, and W93-13 was variant W93R, in which the 93rd tryptophan was substituted with arginine. Figure 3 is a graph comparing the activity of wild-type and variant PlBVMO against 5-dodecanone. Figure 4 is a graph comparing the activity of PlBVMO wild type and variant against 8-pentadecanone. Figure 5 shows the C1s Spectra of the surface of a polyketone film induced by PlBVMO-W93R. From the far left, the C1s Spectra are of an untreated polyketone film, a polyketone film reacted with lipases, and a polyketone film reacted with BVMO and lipases. Figure 6 is a graph showing the weight reduction of polyketone films treated with PlBVMO-W93R and lipase. The treatment case shows the film weight reduction after treatment with PlBVMO-W93R and lipase, while the control case shows the film weight reduction after culture under the same conditions without enzymes. Specific details for implementing the invention
[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.
[0031] In order to develop a Bayer-Billiger monooxygenase variant with significantly improved activity compared to the wild-type enzyme, screening was performed by introducing mutations to the amino acid sequence of the protein and measuring the activity, and as a result, a Bayer-Billiger monooxygenase variant with improved activity against the substrate through amino acid substitution was selected.
[0032] Accordingly, in one aspect, the present invention relates to a Bayer-Billiger monooxygenase variant with enhanced catalytic activity for the Bayer-Billiger oxidation reaction.
[0033] In the present invention, the Bayer-Billiger monooxygenase serving as the template (or wild type) of the variant of the present invention refers to an enzyme that induces a Bayer-Billiger oxidation reaction in which an oxygen atom is inserted between the carbon of the carbonyl group of a substrate (e.g., compound, protein, etc.) and its adjacent carbon.
[0034] In the present invention, the Bayer-Billiger monooxygenase is represented by SEQ ID NO. 1, but is not limited thereto, and should be interpreted to mean a protein in which an amino acid residue is conservatively substituted at a specific amino acid residue position.
[0035] In this specification, "conservative substitution" means a modification of Bayer-Billiger monooxygenase comprising substituting one or more amino acids with amino acids having similar biochemical properties that do not cause a loss of biological or biochemical function of Bayer-Billiger monooxygenase or a variant thereof.
[0036] The term "conservative amino acid substitution" in this invention refers to a substitution in which an amino acid residue is replaced with an amino acid residue having a similar side chain. A class of amino acid residues having a similar side chain is defined in the art and is well known. These classes include amino acids having basic side chains (e.g., lysine, arginine, histidine), amino acids having acidic side chains (e.g., aspartic acid, glutamic acid), amino acids having uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids having non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids having beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids having aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0037] Accordingly, the Bayer-Billiger monooxygenase that serves as the template for the variant of the present invention is interpreted to include not only SEQ ID NO. 1, but also all Bayer-Billiger monooxygenases, recombinant Bayer-Billiger monooxygenases, and fragments thereof that have substantially the same function and / or effect as the same and have amino acid sequence homology of 40% or more, 50% or more, 60% or more, 70% or more, preferably 80% or more, or 85% or more, more preferably 90% or more, 95% or more, most preferably 99% or more.
[0038] The term "fragment" in the present invention refers to a partial fragment of a parent protein that has been cleaved, and may have its C'-terminus and / or N'-terminus cleaved. In the present invention, said fragment refers to a fragment having substantially the same function and / or effect as the Bayer-Billiger monooxygenase of the present invention. For example, said fragment may include a fragment in which a signal sequence has been cleaved from a full-length protein.
[0040] In the present invention, the Bayer-Billiger monooxygenase is favivaculum ravamentiborans represented by SEQ ID NO. 1 ( Parvibaculum lavamentivorans In addition to Bayer-Billiger monooxygenase derived from ) it may be derived from other strains or other organisms. For example, Acinetobacter calcoaceticus ( Acinetobacter calcoaceticus ) Origin BVMO, Oceanicola basensis( Oceanicola batsensis ) Origin BVMO, Pseudomonas fluorescens( Pseudomonas fluorescens ) Origin BVMO, Pseudomonas putida( Pseudomonas putida ) Origin BVMO, or Nocardia Syriasijorzika( Nocardia cyriacigeorgica It may be a BVMO of origin, but is not limited to this.
[0041] In one embodiment of the present invention, it was confirmed that when a variant is produced by substituting a portion of the amino acids of wild-type Bayer-Billiger monooxygenase, it exhibits significantly superior activity against the Bayer-Billiger oxidation reaction.
[0043] Accordingly, in the present invention, the Bayer-Billiger monooxygenase variant may be characterized by including a mutation in the W93 amino acid of the Bayer-Billiger monooxygenase represented by SEQ ID NO. 1.
[0045] The term “variant” of the present invention is used to encompass not only variations of some amino acid residues in the amino acid sequence of a reference sequence (normal Bayer-Billiger monooxygenase sequence; e.g., SEQ ID NO. 1), preferably including substitutions, deletions and / or insertions of amino acid residues, more preferably substitutions of amino acid residues, but also all cases in which deletions of some amino acid residues at the N-terminus or C-terminus occur together with such substitutions, deletions and / or insertions of amino acid residues. In one embodiment of the present invention, the variant was prepared by substituting some amino acids of SEQ ID NO. 1, but is not limited thereto.
[0046] In the present invention, the 'variation' may be characterized as a substitution of amino acids.
[0047] In the present invention, the Bayer-Billiger monooxygenase variant may be characterized by including an amino acid substitution of W93R or W93Q in the Bayer-Billiger monooxygenase represented by SEQ ID NO. 1, and more preferably, may be characterized by including an amino acid substitution of W93R.
[0048] In one embodiment of the present invention, it was confirmed that a Bayer-Billiger monooxygenase variant comprising a W94R amino acid substitution in Bayer-Billiger monooxygenase represented by SEQ ID NO. 1 exhibited the most superior activity, but is not limited thereto.
[0049] The above position of the amino acid residue of the amino acid variation can be accurately numbered using the amino acid sequence represented by SEQ ID NO. 1 as a reference, where “residue Xn” represents residue X corresponding to position n in the amino acid sequence represented by SEQ ID NO. 1, where n is a positive integer and X is an abbreviation for any amino acid residue. For example, “residue W93” refers to amino acid residue W corresponding to position 93 in the amino acid sequence represented by SEQ ID NO. 1.
[0050] In the present invention, "amino acid variation" may be "amino acid substitution Xn," and in one embodiment, refers to an amino acid substitution occurring at amino acid residue X at position n in the amino acid sequence represented by SEQ ID NO. 1, where n is a positive integer and X is an abbreviation for any amino acid residue. For example, "amino acid substitution V93" refers to an amino acid substitution occurring at amino acid residue V corresponding to position 93 in the amino acid sequence represented by SEQ ID NO. 1. "amino acid substitution XnY" in one embodiment refers to an amino acid substitution in which amino acid residue X at position n in the amino acid sequence represented by SEQ ID NO. 1 is substituted with amino acid residue Y.
[0051] In the present invention, when a Bayer-Billiger monooxygenase having an amino acid sequence other than that of SEQ ID NO. 1 used as a reference sequence is used as a reference sequence, an amino acid residue "corresponding" to a specific amino acid residue described with reference to SEQ ID NO. 1 can generally be obtained by aligning the amino acid sequences under optimization conditions. The sequence alignment can be performed by means understood by a person skilled in the art, for example, using software such as BLAST, BLAST-2, ALIGN, NEEDLE, or Megalign (DNASTAR). A person skilled in the art can determine appropriate parameters for use in alignment, including any algorithm necessary to achieve optimal alignment in the full-length sequences being compared.
[0052] The amino acid substitutions of the present invention may be non-conserved substitutions. The non-conserved substitutions may include modifying amino acid residues of a target protein or polypeptide in a non-conserved manner, such as, for example, replacing an amino acid residue having a specific side chain size or specific characteristic (e.g., hydrophilicity) with an amino acid residue having a different side chain size or different characteristic (e.g., hydrophobicity).
[0053] The above amino acid substitutions may also be conserved substitutions. Such conserved substitutions may include altering amino acid residues of a target protein or polypeptide in a conserved manner, for example, by replacing an amino acid residue having a specific side chain size or specific characteristics (e.g., hydrophilicity) with an amino acid residue having the same or similar side chain size or the same or similar characteristics (e.g., still hydrophilicity). Such conserved substitutions generally do not significantly affect the structure or function of the produced protein. In this application, amino acid sequence variants, fragments thereof, or variants thereof with one or more substituted amino acids that are mutants of a fusion protein may include conserved amino acid substitutions that do not significantly alter the structure or function of the protein.
[0054] For example, mutual substitutions between amino acids in each of the following groups may be considered as conservative substitutions in this application:
[0055] Group of amino acids with nonpolar side chains: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine.
[0056] Group of uncharged amino acids with polar side chains: glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
[0057] Negatively charged amino acid group with polar side chains: aspartic acid and glutamic acid.
[0058] Positively charged basic amino acid group: lysine, arginine, and histidine.
[0059] Amino acid groups containing phenyl: phenylalanine, tryptophan, and tyrosine.
[0060] The proteins, polypeptides, and / or amino acid sequences included in the present invention may also be understood to include at least the following ranges: variants or homologues having the same or similar function as said protein or polypeptide.
[0061] In the present invention, the variant may be a protein or polypeptide produced by substitution, deletion, or addition of one or more amino acids compared to a wild-type Bayer-Billiger monooxygenase amino acid sequence. For example, the functional variant may comprise a protein or polypeptide having an amino acid change by substitution, deletion, and / or insertion of at least one amino acid, e.g., 1-30, 1-20, or 1-10, or alternatively, substitution, deletion, and / or insertion of 1, 2, 3, 4, or 5 amino acids. The functional variant may substantially retain the biological properties of the protein or polypeptide prior to the change (e.g., substitution, deletion, or addition). For example, the functional variant may retain 60%, 70%, 80%, 90%, or 100% or more of the biological activity of the protein or polypeptide prior to the change.
[0062] In the present invention, the homologue may be a protein or polypeptide having at least about 80% sequence homology (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) with respect to the amino acid sequence of the protein and / or polypeptide.
[0063] In the present invention, the homology generally refers to similarity, analogousness, or association between two or more sequences. The “percent of sequence homology” can be calculated by comparing two aligned sequences in a comparison window that determines the number of positions where the same nucleic acid base (e.g., A, T, C, G, I) or the same amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) exists, and the number of matching positions in the comparison window (i.e., window size) is divided by the total number of positions to provide the percentage of sequence homology, and the result is multiplied by 100. Alignment for determining the percentage of sequence homology may be performed in various ways known in the art using publicly available computer software, such as, for example, BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art may determine appropriate parameters for sequence alignment, including any algorithms necessary to achieve maximum alignment within the full-length sequences being compared or within a target sequence region. Such homology may also be determined by the following methods: FASTA and BLAST. FASTA algorithms are described, for example, in WR Pearson and DJ Lipman's "Improved Tool for Biological Sequence Comparison", Proc. Natl. Acad. Sci., 85: 2444-2448, 1988; and D, J. Lipman and WRIt is disclosed in Pearson's "Fast and Sensitive Protein Similarity Search", Science, 227:1435-1441, 1989, and a description of the BLAST algorithm can be found in S. Altschul, W. Gish, W. Miller, EW Myers and D. Lipman, "A Basic Local Alignment Search Tool", Journal of Molecular Biology, 215: 403-410, 1990.
[0065] In one embodiment of the present invention, it was confirmed that when the Bayer-Billiger monooxygenase variant of the present invention is used, a significantly higher Bayer-Billiger oxidation reaction can be induced compared to the wild type by using various compounds containing carbonyl groups as substrates. Therefore, the Bayer-Billiger monooxygenase variant of the present invention can be used to oxidize the substrate by Bayer-Billiger using various compounds containing carbonyl groups as substrates, but is not limited thereto.
[0066] In the present invention, the substrate may be a compound containing a carbonyl group, preferably 5-dodecanone or 8-pentadecanone as confirmed in one example, but is not limited thereto.
[0068] In another aspect, the present invention relates to a nucleic acid encoding the Bayer-Billiger monooxygenase variant.
[0069] In another aspect, the present invention relates to a vector containing the nucleic acid.
[0070] In another aspect, the present invention relates to a recombinant microorganism transformed with the nucleic acid or vector.
[0071] In the present invention, the term "nucleic acid" generally refers to an isolated form of nucleotide, deoxyribonucleotide, or ribonucleotide, or any analogue thereof, isolated from the natural environment or artificially synthesized. The nucleic acid of the present invention may be isolated. For example, it may be produced or synthesized by the following methods: (i) in vitro amplification, such as polymerase chain reaction (PCR) amplification; (ii) clonal recombination; (iii) purification, e.g., fractionation by restriction enzyme digestion and gel electrophoresis; or (iv) synthesis, e.g., chemical synthesis. In some embodiments, the isolated nucleic acid is a nucleic acid molecule produced by recombinant DNA technology. In the present invention, the nucleic acid encoding the variant may be produced by various methods known in the art. Such methods include, but are not limited to, restriction fragment work or overlap extension PCR using synthetic oligonucleotides. The manufacturing method and principle can be found in Sambrook et al., *Molecular Cloning*, *A Laboratory Manual*, *Cold Spring Harbor Laboratory Press*, *Cold Spring Harbor*, NY, 1989; and Ausube et al., *Current Protocols in Molecular Biology*, *Greene Publishing and Wiley-Interscience*, *New York*, NY, 1993.
[0072] In the present invention, the term "plasmid" may be used interchangeably with "vector" and generally refers to a nucleic acid molecule capable of self-replicating in a host cell or microorganism by delivering an inserted nucleic acid to a host cell (including a host microorganism). The vector may include a vector primarily used for inserting DNA or RNA into a cell, a vector primarily used for DNA or RNA replication, and a vector primarily used for transcription and / or translational expression of DNA or RNA. The vector may also include a vector having multiple functions. The vector may be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Generally, by culturing a suitable host cell containing the vector, the vector can produce a desired expression product. In the present invention, the vector may contain one or more of the nucleic acids. For example, the vector may contain all the nucleic acid molecules necessary to encode the variant. In this case, only one vector is required to obtain the fusion protein of the present application. In some embodiments, the vector may include a nucleic acid molecule encoding a portion of the variant. Alternatively, the vector may include a nucleic acid molecule for regulating gene expression in the recombinant microorganism, for example. In this case, two or more different vectors may be required to obtain the recombinant microorganism of the present invention.
[0073] Additionally, the vector may include other genes, such as marker genes, that select the vector under appropriate host cells and appropriate conditions. Additionally, the vector may include control elements that ensure the coding region is properly expressed in an appropriate host. Such control elements are well known to those skilled in the art. For example, they may include promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation. In some embodiments, the expression control sequence is a regulatory element. The specific structure of the expression control sequence may vary depending on the function of the species or cell type, but generally includes 5' non-transcription sequences and 5' and 3' non-translation sequences involved in transcription and translation initiation, such as TATA boxes, capped sequences, and CAAT sequences. For example, the 5' non-transcription expression control sequence may include a promoter region, and the promoter region may include a promoter sequence for the transcriptional regulation of a functionally linked nucleic acid. In the present invention, the vector may be pCold, but is not limited thereto, and a person skilled in the art may appropriately select and use a vector commonly used in the art in addition to the vector described above.
[0074] The term “expression control sequence” refers to a DNA sequence essential for the expression of a coding sequence operably linked in a specific host organism. Such control sequences include a promoter for carrying out transcription, an optional operator sequence for regulating such transcription, a sequence coding for a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. For example, a control sequence suitable for prokaryotes includes a promoter, optionally an operator sequence, and a ribosome binding site. For eukaryotes, it includes a promoter, a polyadenylation signal, and an enhancer. The factor that most influences the amount of gene expression in a plasmid is the promoter. As promoters for high expression, SRα promoters and cytomegalovirus-derived promoters are preferably used.
[0075] To express the DNA sequence of the present invention, any of the very diverse expression regulatory sequences may be used in the vector. Examples of useful expression regulatory sequences include, for example, early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, T3 and T7 promoters, the major operator and promoter regions of phage lambda, the regulatory regions of fd code proteins, promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, promoters of said phosphatase, for example Pho5, promoters of the yeast alpha-mating system, and other sequences of configuration and induction known to regulate the expression of genes in prokaryotic or eukaryotic cells or viruses thereof, and various combinations thereof. The T7 RNA polymerase promoter Φ can be usefully used to express proteins in E. coli.
[0076] Nucleic acids are “operably linked” when positioned in a functional relationship with other nucleic acid sequences. This may be a gene and regulatory sequence(s) linked in such a way that an appropriate molecule (e.g., a transcription-activating protein) enables gene expression when it binds to the regulatory sequence(s). For example, DNA for a pre-sequence or secretion leader is operably linked to DNA for a polypeptide when expressed as a pre-sequence protein participating in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence when it influences the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence when it influences the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence when positioned to facilitate translation. Generally, “operably linked” means that the linked DNA sequences are in contact, and in the case of a secretion leader, they are in contact and exist within the reading frame. However, an enhancer does not need to be in contact. The linkage of these sequences is performed by ligation at a convenient restriction enzyme site. If such a site is not present, a synthetic oligonucleotide adaptor or linker is used according to conventional methods.
[0077] As used herein, the term “expression vector” refers to a recombinant carrier into which a fragment of heterogeneous DNA is inserted, generally meaning a fragment of double-stranded DNA. Here, heterogeneous DNA refers to atypical DNA that is not naturally found in host cells. Once inside a host cell, the expression vector can replicate independently of the host chromosomal DNA, and several copies of the vector and its inserted (heterogeneous) DNA may be produced.
[0078] As is well known in the art, in order to increase the expression level of a transfected gene in a host cell, the gene must be operably linked to transcriptional and translational expression regulatory sequences that are functional within the selected expression host. Preferably, the expression regulatory sequences and the gene are contained within a single expression vector that includes both a bacterial selection marker and a replication origin. If the expression host is a eukaryotic cell, the expression vector must additionally include expression markers useful within the eukaryotic expression host.
[0079] A wide variety of expression host / vector combinations may be used to express variants of the present invention. Expression vectors suitable for eukaryotic hosts include, for example, expression regulatory sequences derived from SV40, bovine papillomavirus, anenovirus, adeno-associated virus, cytomegalovirus, and retrovirus. Expression vectors usable for bacterial hosts include bacterial plasmids that may be exemplified by those obtained from E. coli, such as pBluescript, pGEX2T, pUC vector, col E1, pCR1, pBR322, pMB9, and their derivatives; plasmids with a broader host range, such as RP4; phage DNA that may be exemplified by a wide variety of phage lambda derivatives, such as λ10 and λNM989; and other DNA phages, such as M13 and filamentous single-stranded DNA phages. Expression vectors useful for yeast cells are 2μ plasmids and their derivatives. A useful vector for insect cells is pVL 941.
[0080] Microorganisms transformed or transfected by the expression vector described above constitute another aspect of the present invention. As used herein, the term “transformation” means the introduction of DNA into a host so that the DNA becomes replicable as an extrachromosomal factor or through chromosomal integration completion. As used herein, the term “transfection” means the acceptance of an expression vector by a host cell, regardless of whether any coding sequence is actually expressed.
[0081] In the present invention, the terms “host cell,” “cell,” “host microorganism,” and “host” may be used interchangeably and generally refer to a plasmid or vector containing or capable of containing the nucleic acid of the present invention, or a variant of the present invention, or an individual cell, cell line, microorganism, or cell culture capable of expressing proteins or polypeptides whose expression is regulated. The host cell may include progeny of a single host cell. Due to natural, accidental, or deliberate mutations, the progeny cells and the original parent cell may not necessarily be completely identical in morphology or genome, as long as they can express the target protein or polypeptide of the present invention. The host cell may be obtained by transfecting a cell in vitro with a vector of the present invention. The host cell may preferably be a microorganism, for example, Escherichia coli (E. coli).), Rhizobium, Bifidobacterium, Candida, Erwinia, Enterobacter, Pasteurella, Mannheimia, Actinobacillus, Aggregatibacter, Xanthomonas, Vibrio, Azotobacter, Acinetobacter, Ralstonia, Agrobacterium, Rhodobacter, Zymomonas, Bacillus, Staphylococcus, Lactococcus, Streptococcus, It may be selected from the group consisting of Lactobacillus, Clostridium, Corynebacterium, Streptomyces, Bifidobacterium, Cyanobacterium, and Cyclobacterium, but is not limited thereto.
[0083] In one aspect, the present invention relates to a method for producing a Bayer-Billiger monooxygenase variant, comprising the steps of: culturing a recombinant microorganism into which the nucleic acid is introduced to produce a Bayer-Billiger monooxygenase variant; and obtaining the produced Bayer-Billiger monooxygenase variant.
[0084] In the present invention, the recombinant microorganism may be characterized by being cultured in LB medium, but is not limited thereto.
[0085] In one embodiment of the present invention, a vector having nucleic acid encoding the Bayer-Billiger monooxygenase variant of the present invention was introduced into an E. coli BL21(DE3) strain and cultured to produce a Bayer-Billiger monooxygenase variant from the microorganism, and it was confirmed that the Bayer-Billiger monooxygenase variant exhibited significantly higher enzyme activity compared to the wild-type enzyme.
[0087] Bayer-Billiger monooxygenase is an enzyme that induces the Bayer-Billiger oxidation reaction, catalyzing the insertion of an oxygen atom between the carbon of a carbonyl group of a carbon compound and its adjacent carbon. In one embodiment of the present invention, it was confirmed that the Bayer-Billiger oxidation reaction is induced using a carbonyl-containing compound as a substrate with a variant of the Bayer-Billiger monooxygenase of the present invention, and it was confirmed that the enzyme activity for the Bayer-Billiger oxidation reaction of the variant is enhanced compared to the wild-type Bayer-Billiger monooxygenase.
[0088] Accordingly, in one aspect, the present invention relates to a method for Bayer-Billiger oxidizing a compound containing a carbonyl group using the Bayer-Billiger monooxygenase variant or the recombinant microorganism.
[0089] In the present invention, the compound may be a compound containing a carbonyl group, in particular, a linear or cyclic ketone compound, but may be used without limitation as long as it is a compound capable of undergoing Bayer-billiger oxidation, which involves the addition of oxygen between the carbons of the compound to esterify or lactoneize it. Using the Bayer-billiger monooxygenase variant of the present invention can increase the rate of the Bayer-billiger oxidation reaction.
[0091] In one embodiment of the present invention, when a reaction was performed by treating a polyketone with the Bayer-Billiger monooxygenase variant and lipase of the present invention using a polyketone as a substrate, it was confirmed that the polyketone was degraded.
[0092] Accordingly, in one aspect, the present invention relates to a composition for polyketone degradation comprising the above-mentioned Bayer-Billiger monooxygenase variant and lipase.
[0093] In this invention, the term “polyketone” refers to a terpolymer polymerized using carbon monoxide, ethylene, and propylene as monomers. As a novel material with lower raw material and polymerization process costs compared to general engineering plastics such as polyamides, polyesters, and polycarbonates, it is attracting attention as an eco-friendly material capable of replacing existing engineering plastics due to its excellent mechanical properties, heat resistance, chemical resistance, fuel permeability, and wear resistance (Yun ju-ho, et al., Elastomers and composites v.49 no. 1 pp. 37-42 (2014)). Polyketone is [-CH2CH2CO-] n A substance having the chemical formula can be represented by the following chemical formula 1.
[0094] [Chemical Formula 1]
[0095]
[0096] In one embodiment of the present invention, the polyketone may be a polyketone resin commercially available from Hyosung (Korea) and may be a compound represented by the following chemical formula 2, but is not limited thereto.
[0097] [Chemical Formula 2]
[0098]
[0099] In the present invention, the term “lipase” refers to an enzyme that breaks down fat into fatty acids and monoglycerides. It may be used interchangeably with the terms “lipohydrolyzing enzyme” or “lipolytic enzyme” in the same sense.
[0100] In one embodiment of the present invention, it was confirmed that the polyketone was degraded as a result of treating a polyketone film with the Bayer-Billiger monooxygenase variant and lipase. In the present invention, the Bayer-Billiger monooxygenase variant may preferably be a variant comprising an amino acid substitution of W93R, and the lipase is preferably Burkholderia cepacia , Rhizomucor miehei , Mucor miehei It may be derived lipase, but is not limited to this.
[0102] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0104] Example 1: Preparation of Bayer-Billiger monooxygenase variant vector
[0105] [A / G]GXWXXX[F / Y]P[G / M]XXD, one of the major motifs of Type I BVMO observed in PlBVMO, has been reported to interact with FAD as a catalytic residue, and FAD, as a prosthetic group of BMVO, plays a very important role in the formation of nucleophiles for the redox reaction of the substrate together with cofactors (Nguyen, Tien Duc, et al. Biochemical and biophysical research communications 512(3) pp. 564-570 (2019)). Therefore, four sites I55, V66, R89, and W93, adjacent to the active site and FAD, which plays an important role in the catalytic reaction of BVMO, were selected as mutation sites for site-saturation mutagenesis.
[0106] The 93rd amino acid, tryptophan, of PlBVMO forms a total of three hydrogen bonds with alanine (64), glutamine (95), and arginine (97) (Nguyen, Tien Duc, et al. Biochemical and biophysical research communications 512(3) pp. 564-570 (2019)). It was confirmed that due to a site-saturation mutagenesis, the 93rd amino acid residue of PlBVMO is substituted from tryptophan to arginine, allowing additional hydrogen bonds to form between the carbonyl oxygen of the tryptophan backbone (56th amino acid) and the hydrogen of the substituted arginine side chain, and that the size of the side chain has decreased. It is predicted that these structural changes will contribute to the activity of PlBVMO-W93R.
[0107] Accordingly, the inventors constructed a vector inserted with a BVMO variant coding gene by inducing site-saturation mutations through mutagenic PCR. Deposit number KCTC 22775 BVMO coding gene of Parvibaculum lavamentivorans ( PlBVMOPCR was performed using (SEQ No. 4) as a template, primers containing a degenerate codon NNN at the 93rd amino acid position of BVMO indicated by SEQ No. 1, and primers containing the overlapping ends of pCold cleaved by restriction enzymes NdeI and PstI. To cleave vector pCold I with restriction enzymes NdeI and PstI, a reaction solution composed of 10 μL of pCold I vector, 5 μL of 10*Buffer, 0.5 μL of NdeI, 0.5 μL of PstI, and 34 μL of dH2O was prepared and reacted at 37°C for 2 hours. After the reaction was completed, the cleaved vector DNA was obtained by performing electrophoresis and gel purification on the reaction solution. The vector pCold was purchased from Takara, and the restriction enzymes NdeI and PstI were purchased from enzynomics. The sequence numbers of the amino acid sequence of Bayer-Bligger monooxygenase and the base sequence of its coding gene are shown in Table 1 below.
[0108] Proteins and gene sequences Sequence number Amino acid sequence of PlBVMO-WT 1 Amino acid sequence of PlBVMO-W93-11 2 Amino acid sequence of PlBVMO-W93-13 3 nucleotide sequence of PlBVMO-WT 4 Nucleotide sequence of W93-11 (W93Q) 5 Nucleotide sequence of W93-13 (W93R) 6
[0110] Gel purification was performed on the two amplified PCR fragments using the MEGAquick-spin™plus Fragment DNA Purification kit (iNtRON Biotechnology, Korea), and overlap extension PCR was performed using the two purified PCR fragments as templates to induce a single-site saturated mutation PlBVMO DNA fragments of the gene were constructed. The generated DNA fragments were subjected to Gibson assembly with pCold cleaved with NdeI and XbaI to pCold- PlBVMO Variant vectors were constructed (Fig. 1). The vectors were transformed into E. coli Top10 strains. The primers used to construct the vectors are shown in Table 2 below.
[0111] primer nucleotide sequence (5' → 3') Sequence number PlBVMO-F ATGAGTTCGGTACAATCCAGCC 7 PlBVMO-R TCAATCCAAGACGAATCCCTCATAA 8 pCold-PlBVMO-F GTGCATCATCATCATCATCATATCGAAGGTAGGCATATGAGTTCGGTACAATCCAGCC 9 pCold-PlBVMO-R CTGTGCTTTTAAGCAGAGATTACCTATCTAGACTGCATCAATCCAAGACGAATCCCTCATAA 10
[0113] Example 2. Bayer-Billiger monooxygenase variant screening
[0114] For the primary screening of PlBVMO variant proteins, an activity assay was performed using the crude extract of the above-transformed E. coli Top 10 strains. pCold- PlBVMO A single colony containing the variant plasmid was randomly selected and inoculated into 10 mL of LB medium containing 50 μg / mL ampicillin. When the OD600 value of the culture reached 0.8, isopropyl β-D-1-thiogalactopyranoside (isopropyl β; IPTG) was added to a concentration of 1 mM, and the culture was incubated at 15°C for about 12 hours to produce the PlBVMO variant protein.
[0115] Subsequently, cells were harvested by centrifugation at 13,000 rpm at 4°C for 5 minutes. The harvested cells were suspended in 50 mM Tris-HCl (pH 8.0) buffer, and after centrifugation, the supernatant was removed to separate the cells. The separated cells were resuspended in 50 mM Tris-HCl (pH 8.0) buffer, the cells were placed in contact with ice, sonication was performed, and after centrifugation at 13,000 rpm at 4°C for 5 minutes, the supernatant was removed to obtain the crude extract remaining as a pellet. The crude extract contains PlBVMO variant protein.
[0116] PlBVMO variant proteins with enhanced activity were initially selected using the crude extract containing the above-mentioned PlBVMO variant proteins. To evaluate BVMO activity, 1 mL of a reaction mixture was prepared by adding substrate and NADPH to the crude extract containing wild-type PlBVMO protein and PlBVMO variant proteins until concentrations of 0.5 mM and 0.2 mM, respectively. Immediately after preparing the reaction mixture, activity was evaluated by measuring the absorbance of NADPH using a spectrophotometer at a wavelength of 340 nm for 60 seconds at 25°C. Protein content was determined by the Bradford assay using bovine serum albumin (BSA) as a standard. Since BVMO utilizes NADPH as a cofactor, a decrease in NADPH indicates that the enzyme exhibited activity and catalyzed the Bayer-Billiger oxidation reaction.
[0117] Through random screening of PlBVMO variants using crude extracts, W93-11 and W93-13 variants with high activity against 5-dodecanone and 8-pentadecanone substrates were selected (Fig. 2).
[0119] Example 3. Preparation of Bayer-Billiger monooxygenase variant and analysis of its activity
[0120] Mini-prep was performed on E. coli Top10 containing vectors with W93-11 and W93-13 genes selected through random screening to extract the vectors, and the extracted vectors were transformed into E. coli BL21(DE3) strains. The E. coli Top10 strains were purchased from Thermo Fisher, and the E. coli BL21(DE3) strains were purchased from enzynomics. As a result of analyzing the nucleotide sequences of the selected W93-11 and W93-13, it was confirmed that the nucleotide sequences coding for the 93rd amino acid were replaced from TGG(WT) to CAG(W93-11) and CGA(W93-13), respectively, and that tryptophan, the 93rd amino acid, was replaced with glutamine and arginine.
[0121] E. coli pCold-PlBVMO / BL21 strains containing a plasmid were selected by culturing in LB medium containing the antibiotic ampicillin. 5 mL of LB medium was added to a test tube containing the solution of the strain, and seed culture was performed under conditions of 37°C and 200 rpm. This was inoculated at 1% into 100 mL of LB medium and cultured, and then finally subcultured by inoculating at 5% into 1 L of LB medium. When the OD600 value reached approximately 0.8, isopropylgalactoside (IPTG) was added until the concentration reached 1 mM to express the BVMO coding gene, and after incubating at 15°C for about 15 hours, 15,000 g of cells were harvested at 4°C for 5 minutes for purification.
[0122] The obtained cells were diluted with 50 mM Tris-HCl buffer (pH 8.0) and sonicated on ice to lyse them. Afterward, the cells were centrifuged at 15,000 g for 30 minutes at 4°C, and the supernatant containing protein was separated. The protein was then purified using a Ni-NTA column (Millipore). After washing with 30 mM imidazole buffer, the wild-type and mutant PlBVMO were eluted with a buffer containing 300 mM imidazole. The imidazole was washed away from the elution fraction using a 10 kDa MWCO Amicon centrifugal concentrator (Millipore), and the wild-type and mutant PlBVMO were concentrated.
[0123] Since BVMO utilizes NADPH as a cofactor, the decrease in NADPH was measured by checking the change in absorbance at a wavelength of 340 nm for 60 seconds to analyze the activity of BVMO. A 1 mL sample for the assay was prepared by adding 10 μL of 100 μM BVMO, 10 μL of 50 μM substrate, and 10 μL of 20 μM NADPH to 50 mM Tris-HCl buffer (pH 8.0). 5-dodecanone and 8-pentadecanone, compounds with a structure in which the carbonyl group is located in the center, were used as substrates.
[0124] As a result of the activity of purified PlBVMO wild-type and variants against 5-dodecanone and 8-pentadecanone (Figs. 3 and 4), compared to wild-type PlBVMO;
[0125] The PlBVMO-W93Q variant showed approximately 0.5 times reduced activity against 8-pentadecanone, and no significant difference in activity against 5-dodecanone.
[0126] The PlBVMO-W93R variant showed increased activity against 8-pentadecanone and significantly higher activity against 5-dodecanone, approximately 1.8 times.
[0128] Example 4. Confirmation of polyketone film degradation ability using a Bayer-Billiger monooxygenase variant
[0129] Example 4-1: Polyketone Degradation Method
[0130] Polyketone (PK) films were cut into 0.5 cm x 0.5 cm pieces for the experiment. Three polyketone films were placed in a glass vial containing 3 mL of 50 mM Tris-HCl (pH 8.0) buffer solution in which 0.5 mg / mL PlBVMO-W93R protein and 1 mM NADPH were dissolved. The vial was incubated at 30°C and 150 rpm for 3 weeks, with the reaction solution exchanged twice daily. After 3 weeks, the films were removed, and any remaining protein was washed with 2% SDS solution and 20% (v / v) ethanol solution, followed by a final wash with distilled water. The washed films were dried in a 70°C oven.
[0131] Dried polyketone film purchased from Sigma-Aldrich Burkholderia cepacia , Rhizomucor miehei , Mucor miehei Three types of derived lipases were each dissolved at 0.1 mg / mL in a new vial containing 3 mL of 50 mM phosphate (pH 7.0) buffer solution. The vials were incubated at 40°C and 150 rpm for one week, and the reaction solution was replaced every two days. Afterward, the film was washed and dried according to the same procedure as above.
[0133] Example 4-2: Confirmation of Polyketone Degradation via XSP Analysis
[0134] In this example, X-ray photoelectron spectroscopic (XSP) analysis and weight loss measurement were performed on polyketone films to evaluate the activity of PlBVMO-W93R on polyketone films. To analyze changes in the chemical bonding state on the surface of the polyketone films, XPS analysis was conducted using an X-ray photoelectron spectrometer (Thermo Fisher Scientific, K-ALPHA) at the Korea Polymer Testing & Research Institute (KPRI). Polyketone films untreated with any enzyme, treated only with lipase, and treated with both the Bayer-Billiger monooxygenase variant (PlBVMO-W93R) and lipase were analyzed. X-rays were applied under conditions of 12,000 V, 6 mA, and 72 W. The weight of the polyketone films was measured using a microbalance (Mettler Toledo, WXTS3DU). The weight of the polyketone film before treatment (W non-treated film Measure ) and, Pl Polyketone film weight (W) after treatment with BVMO-W93R and lipase treated film The weight loss of polyketone film was calculated according to the following mathematical formula 1 by measuring ).
[0135] [Mathematical Formula 1]
[0136] Weight loss of polyketone film (%) = 100 x (W non-treated film - W treated film ) / W non-treated film
[0138] Looking at the XPS analysis results, C of the untreated polyketone film and the polyketone film treated only with lipase is shown. 1sIn the spectra, peaks for CC bonds were detected at 285 eV, CO bonds at 286.3 eV, and C=O bonds at 287.7 eV. On the surface of the polyketone film treated with PlBVMO-W93R and lipase, an additional peak for OC=O bonds was detected at 288.7 eV, and the CO peak appeared to be enlarged. This appears to be a peak resulting from the hydrolysis of ester bonds generated by PlBVMO-W93R by lipase, which produces carboxylic acids and alcohols (Fig. 5).
[0139] Example 4-3: Evaluation of Resolution through Measurement of Weight Loss of Polyketone Film
[0140] BVMO is an enzyme that catalyzes the insertion of oxygen next to a carbonyl group. It is difficult to evaluate enzyme activity by measuring the increased weight of the polyketone film due to the inserted oxygen atom. Therefore, the activity of PlBVMO-W93R was indirectly evaluated by reacting a polyketone film previously reacted with PlBVMO-W93R with three lipases reported to degrade polymers and measuring the weight loss.
[0141] After treatment with PlBVMO-W93R and lipase, the weight of the polyketone film decreased by about 1.7% (Fig. 6). This result, along with XPS analysis data, supports the fact that PlBVMO-W93R is active on polyketone films.
Claims
Claim 1 A Bayer-Billiger monooxygenase variant characterized by including an amino acid substitution of W93R in Bayer-Billiger monooxygenase represented by SEQ ID NO.
1. Claim 2 Nucleic acid encoding the Bayer-Billiger monooxygenase variant of claim 1. Claim 3 A recombinant vector containing the nucleic acid of paragraph 2. Claim 4 A recombinant microorganism into which the nucleic acid of paragraph 2 or the recombinant vector of paragraph 3 has been introduced. Claim 5 A method for producing a Bayer-Billiger monooxygenase variant comprising the steps of: culturing the recombinant microorganism of claim 4 to produce a Bayer-Billiger monooxygenase variant; and obtaining the produced Bayer-Billiger monooxygenase variant. Claim 6 A method for Bayer-Billiger oxidizing a carbonyl group-containing compound using the Bayer-Billiger monooxygenase variant of claim 1. Claim 7 A method for oxidizing a carbonyl group-containing compound using the recombinant microorganism of claim 4. Claim 8 A composition for polyketone degradation comprising a Bayer-Billiger monooxygenase variant and lipase according to claim 1.
Citation Information
Patent Citations
Novel Baeyer-Villiger monooxygenase BVMOsm1 from Metagenome
KR1020150142242A
